Phaseline

Companies › NanoRay Biotech

NanoRay Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Auger Molecular Therapy (AMT) / IUdR
Iodinated thymidine analogue (IUdR) incorporated into cancer cell DNA; tuned X-ray irradia
–Phase 1Malignant Fungating WoundDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04807257Auger Molecular Therapy (AMT) / IUdRPhase 1Malignant Fungating WoundOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.